

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/216217 A1

(51) International Patent Classification:

A61K 39/12 (2006.01) C07K 14/155 (2006.01)
A61K 39/00 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2024/024503

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

12 April 2024 (12.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/459,449 14 April 2023 (14.04.2023) US
63/547,796 08 November 2023 (08.11.2023) US
63/549,262 02 February 2024 (02.02.2024) US

Published:

— with international search report (Art. 21(3))

(71) Applicants: **BIONTECH SE** [DE/DE]; An der Goldgrube
12, 55131 Mainz (DE). **THE GENERAL HOSPITAL
CORPORATION** [US/US]; 55 Fruit Street, Boston, Mass-
achusetts 02114 (US).

(72) Inventors: **LE DOUCE, Valentin**; c/o BioNTech SE,
An der Goldgrube 12, 55131 Mainz (DE). **ESAULOVA,
Ekaterina**; c/o BioNTech US Inc., 40 Erie Street, Suite
110, Cambridge, Massachusetts 02139 (US). **KAXIRAS,
Daphne**; c/o BioNTech US Inc., 40 Erie Street, Suite
110, Cambridge, Massachusetts 02139 (US). **ROONEY,
Michael Steven**; c/o BioNTech US Inc., 40 Erie Street,
Suite 110, Cambridge, Massachusetts 02139 (US). **AD-
DONA, Theresa**; c/o BioNTech US Inc., 40 Erie Street,
Suite 110, Cambridge, Massachusetts 02139 (US). **SAHIN,
Ugur**; c/o BioNTech SE, An der Goldgrube 12, 55131
Mainz (DE). **GAIHA, Gaurav**; 96 Country Drive, Weston,
Massachusetts 02493 (US).

(74) Agent: **SCHONEWALD, Stephanie L.** et al.; Choate, Hall
& Stewart LLP, Two International Place, Boston, Massachu-
setts 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: HIV VACCINE

(57) Abstract: The present invention concerns compositions comprising an RNA molecule, wherein the RNA molecule comprises an expression cassette encoding an immunogenic peptide, which peptide comprises at least two fragments, wherein each fragment comprises at least one epitope, wherein the epitope is derived from an amino acid sequence encoded by the human immunodeficiency virus (HIV) and medical preparations comprising such compositions. Furthermore, the invention concerns methods for preventing or treating HIV.

WO 2024/216217 A1